Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations from microdystrophin expression down to muscle integrity are important and pointed in the right direction. Plus, why the company secured a $200M raise before releasing the data publicly.
Fler avsnitt av BiotechTV - News
Visa alla avsnitt av BiotechTV - NewsBiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
